SLC6A3 and body mass index in the prostate, lung, colorectal and ovarian cancer screening trial

Elizabeth M. Azzato, Lindsay M. Morton, Andrew W. Bergen, Sophia S. Wang, Nilanjan Chatterjee, Paul Kvale, Meredith Yeager, Richard B. Hayes, Stephen J. Chanock, Neil E. Caporaso

Research output: Contribution to journalArticle

Abstract

Background: To investigate the contribution of the dopamine transporter to dopaminergic reward-related behaviors and anthropometry, we evaluated associations between polymorphisms at the dopamine transporter gene(SLC6A3) and body mass index (BMI), among participants in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Methods: Four polymorphisms (rs6350, rs6413429, rs6347 and the 3′ variable number of tandem repeat (3′ VNTR) polymorphism) at the SLC6A3 gene were genotyped in 2,364 participants selected from the screening arm of PLCO randomly within strata of sex, age and smoking history. Height and weight at ages 20 and 50 years and baseline were assessed by questionnaire. BMI was calculated and categorized as underweight, normal, overweight and obese (A-C-G-9 = 0.80, 95% CI 0.65-0.99, p = 0.04) and obese individuals (A-C-G-* is referent; ORA-C-G-9 = 0.70, 95% CI 0.49-0.99, p = 0.04) were less likely to possess the haplotype with the 3'variant allele (A-C-G-9). Conclusion: Our results support a role of genetic variation at the dopamine transporter gene, SLC6A3, as a modifier of BMI.

Original languageEnglish (US)
Article number9
JournalBMC Medical Genetics
Volume10
DOIs
StatePublished - Jan 30 2009
Externally publishedYes

Fingerprint

Dopamine Plasma Membrane Transport Proteins
Early Detection of Cancer
Ovarian Neoplasms
Colorectal Neoplasms
Lung Neoplasms
Prostatic Neoplasms
Body Mass Index
Genes
Minisatellite Repeats
Anthropometry
Thinness
Reward
Haplotypes
Prostate
Smoking
History
Alleles
Weights and Measures
Lung

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

SLC6A3 and body mass index in the prostate, lung, colorectal and ovarian cancer screening trial. / Azzato, Elizabeth M.; Morton, Lindsay M.; Bergen, Andrew W.; Wang, Sophia S.; Chatterjee, Nilanjan; Kvale, Paul; Yeager, Meredith; Hayes, Richard B.; Chanock, Stephen J.; Caporaso, Neil E.

In: BMC Medical Genetics, Vol. 10, 9, 30.01.2009.

Research output: Contribution to journalArticle

Azzato, EM, Morton, LM, Bergen, AW, Wang, SS, Chatterjee, N, Kvale, P, Yeager, M, Hayes, RB, Chanock, SJ & Caporaso, NE 2009, 'SLC6A3 and body mass index in the prostate, lung, colorectal and ovarian cancer screening trial', BMC Medical Genetics, vol. 10, 9. https://doi.org/10.1186/1471-2350-10-9
Azzato, Elizabeth M. ; Morton, Lindsay M. ; Bergen, Andrew W. ; Wang, Sophia S. ; Chatterjee, Nilanjan ; Kvale, Paul ; Yeager, Meredith ; Hayes, Richard B. ; Chanock, Stephen J. ; Caporaso, Neil E. / SLC6A3 and body mass index in the prostate, lung, colorectal and ovarian cancer screening trial. In: BMC Medical Genetics. 2009 ; Vol. 10.
@article{6f2c80302112487380adea5ff8f210a4,
title = "SLC6A3 and body mass index in the prostate, lung, colorectal and ovarian cancer screening trial",
abstract = "Background: To investigate the contribution of the dopamine transporter to dopaminergic reward-related behaviors and anthropometry, we evaluated associations between polymorphisms at the dopamine transporter gene(SLC6A3) and body mass index (BMI), among participants in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Methods: Four polymorphisms (rs6350, rs6413429, rs6347 and the 3′ variable number of tandem repeat (3′ VNTR) polymorphism) at the SLC6A3 gene were genotyped in 2,364 participants selected from the screening arm of PLCO randomly within strata of sex, age and smoking history. Height and weight at ages 20 and 50 years and baseline were assessed by questionnaire. BMI was calculated and categorized as underweight, normal, overweight and obese (A-C-G-9 = 0.80, 95{\%} CI 0.65-0.99, p = 0.04) and obese individuals (A-C-G-* is referent; ORA-C-G-9 = 0.70, 95{\%} CI 0.49-0.99, p = 0.04) were less likely to possess the haplotype with the 3'variant allele (A-C-G-9). Conclusion: Our results support a role of genetic variation at the dopamine transporter gene, SLC6A3, as a modifier of BMI.",
author = "Azzato, {Elizabeth M.} and Morton, {Lindsay M.} and Bergen, {Andrew W.} and Wang, {Sophia S.} and Nilanjan Chatterjee and Paul Kvale and Meredith Yeager and Hayes, {Richard B.} and Chanock, {Stephen J.} and Caporaso, {Neil E.}",
year = "2009",
month = "1",
day = "30",
doi = "10.1186/1471-2350-10-9",
language = "English (US)",
volume = "10",
journal = "BMC Medical Genetics",
issn = "1471-2350",
publisher = "BioMed Central",

}

TY - JOUR

T1 - SLC6A3 and body mass index in the prostate, lung, colorectal and ovarian cancer screening trial

AU - Azzato, Elizabeth M.

AU - Morton, Lindsay M.

AU - Bergen, Andrew W.

AU - Wang, Sophia S.

AU - Chatterjee, Nilanjan

AU - Kvale, Paul

AU - Yeager, Meredith

AU - Hayes, Richard B.

AU - Chanock, Stephen J.

AU - Caporaso, Neil E.

PY - 2009/1/30

Y1 - 2009/1/30

N2 - Background: To investigate the contribution of the dopamine transporter to dopaminergic reward-related behaviors and anthropometry, we evaluated associations between polymorphisms at the dopamine transporter gene(SLC6A3) and body mass index (BMI), among participants in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Methods: Four polymorphisms (rs6350, rs6413429, rs6347 and the 3′ variable number of tandem repeat (3′ VNTR) polymorphism) at the SLC6A3 gene were genotyped in 2,364 participants selected from the screening arm of PLCO randomly within strata of sex, age and smoking history. Height and weight at ages 20 and 50 years and baseline were assessed by questionnaire. BMI was calculated and categorized as underweight, normal, overweight and obese (A-C-G-9 = 0.80, 95% CI 0.65-0.99, p = 0.04) and obese individuals (A-C-G-* is referent; ORA-C-G-9 = 0.70, 95% CI 0.49-0.99, p = 0.04) were less likely to possess the haplotype with the 3'variant allele (A-C-G-9). Conclusion: Our results support a role of genetic variation at the dopamine transporter gene, SLC6A3, as a modifier of BMI.

AB - Background: To investigate the contribution of the dopamine transporter to dopaminergic reward-related behaviors and anthropometry, we evaluated associations between polymorphisms at the dopamine transporter gene(SLC6A3) and body mass index (BMI), among participants in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Methods: Four polymorphisms (rs6350, rs6413429, rs6347 and the 3′ variable number of tandem repeat (3′ VNTR) polymorphism) at the SLC6A3 gene were genotyped in 2,364 participants selected from the screening arm of PLCO randomly within strata of sex, age and smoking history. Height and weight at ages 20 and 50 years and baseline were assessed by questionnaire. BMI was calculated and categorized as underweight, normal, overweight and obese (A-C-G-9 = 0.80, 95% CI 0.65-0.99, p = 0.04) and obese individuals (A-C-G-* is referent; ORA-C-G-9 = 0.70, 95% CI 0.49-0.99, p = 0.04) were less likely to possess the haplotype with the 3'variant allele (A-C-G-9). Conclusion: Our results support a role of genetic variation at the dopamine transporter gene, SLC6A3, as a modifier of BMI.

UR - http://www.scopus.com/inward/record.url?scp=60049091289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60049091289&partnerID=8YFLogxK

U2 - 10.1186/1471-2350-10-9

DO - 10.1186/1471-2350-10-9

M3 - Article

VL - 10

JO - BMC Medical Genetics

JF - BMC Medical Genetics

SN - 1471-2350

M1 - 9

ER -